Huperzine A ameliorates obesity-related cognitive performance impairments involving neuronal insulin signaling pathway in mice
Huperzine A ameliorates obesity-related cognitive performance impairments involving neuronal insulin signaling pathway in mice
复制标题
DOI:
10.1038/s41401-019-0257-1
复制
发表时间:
2019-06
影响因子:
8.2
通讯作者:
Hongying Wang;Min Wu;Jun-ling Diao;Jibin Li;Yu-xiang Sun;Xiao Xiao-Xiao
中科院分区:
文献类型:
--
作者:
Hongying Wang;Min Wu;Jun-ling Diao;Jibin Li;Yu-xiang Sun;Xiao Xiao-Xiao
Type 2 diabetes (T2D) and Alzheimer’s disease (AD) share several common pathophysiological features. Huperzine A (Hup A), a Lycopodium alkaloid extracted from the Chinese herb mossHuperzia serrata, is a specific and reversible inhibitor of acetylcholinesterase, which is clinically used for the treatment of AD. In this study, we investigated whether Hup A improved the metabolic and cognitive functions in the high fat-induced (HFD) obese mice and geneticob/obmice. HFD andob/obmice were treated with Hup A (0.1, 0.3 mg · kg−1· d−1, ig) for 3 months. Body weight was monitored and glucose tolerance tests were performed. Novel object recognition test and Morris water maze assay were conducted to evaluate the cognitive functions. We found that the Hup A treatment had no significant effect on peripheral metabolism of obese mice, whereas Hup A (0.1, mg · kg−1· d−1) improved both the abilities of object recognition and spatial memory in HFD-fed mice, but not inob/obmice. Furthermore, Hup A treatment significantly upregulated the insulin and phosphorylated Akt levels in the cortex of HFD-fed mice, but notob/obmice. In addition, Hup A (0.3, mg · kg−1· d−1) significantly decreased cortical β-secretase (BACE1) expression. In conclusion, these results demonstrate that treatment with Hup A (0.1, mg · kg−1· d−1) can effectively improve the cognitive functions, at least in diet-induced obese mice.